TcrossGlobal

Inclisiran-based Strategy Versus Individually Optimized Lipid-lowering Therapy: The VICTORION-Difference Study

The VICTORION-Difference trial demonstrated that among patients at high cardiovascular risk who failed to achieve LDL-C targets despite statin therapy, an inclisiran-based treatment strategy was associated with a significantly higher rate of LDL-C target achievement compared with individually optimized lipid-lowering therapy alone, according to a study presented by Dr. Ulf Landmesser, Deutsches Herzzentrum der Charite, Germany, in the Hot Line session at the ESC Congress 2025.

The trial enrolled 1,770 patients (≥55 mg/dL for very high-risk patients and ≥70 mg/dL for hig...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.